Company Information

  

Address: 830 WINTER ST  
City: WALTHAM 
State: MA 
Zip Code: 02451 
Telephone: (781)895-0600 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biotechnology company focused on developing innovative antibody-drug conjugate, or ADC, therapies that meaningfully improve the lives of people with cancer. An ADC with our proprietary technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of our potent anti-cancer agents as a "payload" to kill the tumor cell once the ADC has bound to its target. ADCs are an expanding approach to the treatment of cancer, with four approved products and the number of agents in development growing significantly in recent years. We have established a leadership position in ADCs. Our proprietary portfolio is led by mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, or FR?.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.08NAN/E
12/2017-0.98NAN/E
06/2017-1.08NAN/E
03/2017-1.50NAN/E
12/2016-1.81NAN/E
09/2016-1.79NAN/E
06/2016-1.67NAN/E
03/2016-1.56NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.09Total Liab/Total Assets1.06
Net Inc/Total Assets-0.33Total Liab/Inv Cap1.31
Net Inc/Inv Cap-0.40Total Liab/Comm Equity0.31
Pretax Inc/Net Sales-0.83Interest Coverage Ratio-30.58
Net Inc/Net Sales-0.83Curr Debt/EquityNA
Cash Flow/Net Sales0.07LTD/Equity-0.11
SG&A/NetSales0.29Total Debt/Equity-0.11
Asset Utilization   Liquidity  
Net Receivables Turnover30.70Quick Ratio4.94
Inventory TurnoverNACurrent Ratio4.96
Inventory Day SalesNANet Rec/Curr Assets0.02
Net Sales/Work Cap0.52Inv/Curr Assets0.00
Net Sales/PP&E7.94  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 19.82 39.45 8.48 39.02
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 10.00 9.05 7.91 8.84
Operating Income -36.74 -9.84 -31.12 -5.14
Interest Exp 0.02 0.03 0.76 1.13
Pretax Income -38.61 -13.12 -56.68 -8.87
Other Income -1.85 -3.25 -24.80 -2.61
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -38.61 -13.12 -56.68 -8.87

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 218.38 267.11 194.85 150.34
Receivables - Total 18.96 5.23 5.12 2.83
Inventories - Total 0.37 1.04 2.24 3.48
Total Current Assets 247.43 276.34 206.96 161.41
Net Property, Plant & Equipment 12.85 14.54 15.62 16.82
Total Assets 264.97 294.68 225.70 181.38
Liabilities        
Accounts Payable 37.21 35.80 29.10 24.70
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 66.23 55.77 73.66 67.35
Long-Term Debt 2.05 2.05 3.02 97.30
Total Liabilities 301.28 312.57 336.99 354.61
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 1.33 1.33 1.16 0.90
Retained Earnings -1,053.11 -1,028.58 -1,015.46 -958.78
Treasury Stock NA NA NA NA
Total Stockholders' Equity -36.31 -17.90 -111.30 -173.23
Total Liabilities and Stockholders' Equity 264.97 294.68 225.70 181.38

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -49.96 -29.41 45.93 24.08
Net Cash Provided by Investing Activities -1.03 -0.27 -0.07 -0.34
Net Cash Provided by Financing Activities 2.26 101.93 -1.35 0.03

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201216.36-73.32-1.12
12/201335.53-72.81-0.37
12/201585.54-60.74-1.44
12/201660.00-144.82-1.81
12/2017115.45-96.01-0.98
Growth Rates62.99----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18240104,77571.41




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.